Search details
1.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Eur Radiol
; 33(2): 1174-1184, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-35976398
2.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34431518
3.
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
Int J Cancer
; 150(8): 1341-1349, 2022 04 15.
Article
in English
| MEDLINE | ID: mdl-34807464
4.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35637412
5.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Br J Cancer
; 124(3): 587-594, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33154570
6.
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Int J Cancer
; 147(9): 2493-2502, 2020 11 01.
Article
in English
| MEDLINE | ID: mdl-32339253
7.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Article
in English
| MEDLINE | ID: mdl-30982686
8.
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Anticancer Drugs
; 31(8): 856-865, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32639280
9.
Acute sedation-associated complications in GI endoscopy (ProSed 2 Study): results from the prospective multicentre electronic registry of sedation-associated complications.
Gut
; 68(3): 445-452, 2019 03.
Article
in English
| MEDLINE | ID: mdl-29298872
10.
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Int J Cancer
; 142(5): 1047-1055, 2018 03 01.
Article
in English
| MEDLINE | ID: mdl-29047142
11.
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Br J Cancer
; 119(3): 296-302, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29988111
12.
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Int J Cancer
; 140(8): 1918-1925, 2017 Apr 15.
Article
in English
| MEDLINE | ID: mdl-28032641
13.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-27575024
14.
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
BMC Cancer
; 16: 699, 2016 08 31.
Article
in English
| MEDLINE | ID: mdl-27582078
15.
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Digestion
; 93(3): 229-33, 2016.
Article
in English
| MEDLINE | ID: mdl-27089254
16.
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Int J Cancer
; 137(3): 678-85, 2015 Aug 01.
Article
in English
| MEDLINE | ID: mdl-25530271
17.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25088940
18.
Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.
JAMA Netw Open
; 7(1): e2352830, 2024 Jan 02.
Article
in English
| MEDLINE | ID: mdl-38261316
19.
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).
Oncol Res Treat
; 47(6): 251-261, 2024.
Article
in English
| MEDLINE | ID: mdl-38565089
20.
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer.
Curr Oncol
; 30(6): 5828-5834, 2023 06 17.
Article
in English
| MEDLINE | ID: mdl-37366919